Robert Beardsley
Chief Executive Officer Cirius Therapeutics
Seminars
Wednesday 16th September 2026
Tailoring Combination Strategies to Address Disease Heterogeneity & Improve Therapeutic Outcomes
2:00 pm
- Evaluating how distinct metabolic and fibrotic disease drivers contribute to patient heterogeneity to identify high-value responder populations, enabling more targeted development strategies and improving therapeutic efficacy
- Assessing the potential of combination approaches that address complementary disease mechanisms to overcome variability in treatment response, enabling enhanced clinical benefit and improving outcomes across broader patient populations
- Leveraging clinical and biological insights to match therapies to patients most likely to benefit, improving trial precision and supporting the development of more effective and differentiated treatment paradigms
Wednesday 16th September 2026
Panel Discussion: Balancing Differentiation, Combination Strategies & Commercial Reality to Define the Next Generation of Successful MASH Therapies
4:10 pm
- Evaluating how developers can differentiate new therapies within an increasingly competitive landscape to demonstrate meaningful clinical value, enabling stronger positioning and improving future adoption
- Assessing when combination approaches are likely to provide the greatest therapeutic advantage over monotherapy strategies, improving development prioritization and maximizing long-term patient benefit
- Defining the clinical, regulatory and commercial attributes required for future therapies to succeed beyond initial approval, strengthening development decision-making and supporting long-term market impact
